We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Denies Prometheus’ Petition on Shared REMS Negotiations
FDA Denies Prometheus’ Petition on Shared REMS Negotiations
October 23, 2013
The FDA rejected most of Prometheus Laboratories’ citizen petition on a single shared risk evaluation and mitigation strategy (REMS), rebutting claims that negotiations with a generic competitor on a shared system could violate antitrust laws.